Table 4.

Risks factors for graft failure, grade II-IV acute and chronic GVHD

OutcomesEvents/evaluableHR (95% CI)P
Graft failure
 Age at transplantation, y
  ≤649/6381.00.02
  7-1543/4391.30 (0.86-1.96).21
  16-257/333.03 (1.36-6.73).006
 Donor type
  HLA-matched relative58/6771.00<.001
  HLA-mismatched relative17/782.84 (1.65-4.88)<.001
  HLA-matched unrelated13/2520.61 (0.33-1.11).10
  HLA-mismatched unrelated11/1031.31 (0.68-2.50).42
Acute GVHD
Age at transplantation, y
  ≤693/6341.00.002
  7-1578/4361.10 (0.71-1.70).66
  16-2510/332.23 (1.30-3.84).003
 Donor type
  HLA-matched relative80/6741.00<.001
  HLA-mismatched relative27/773.33 (2.15-5.17)<.001
  HLA-matched unrelated54/2512.44 (1.72-3.46)<.001
  HLA-mismatched unrelated20/1011.94 (1.19-3.16).008
 Transplant period
  2012-201685/6531.00<.001
  2006-201168/3381.70 (1.23-2.35).001
  2000-200528/1122.50 (1.61-4.00)<.001
Chronic GVHD
 Donor type
  HLA-matched relative52/6271.00<.001
  HLA-mismatched relative14/702.64 (1.42-4.89).002
  HLA-matched unrelated21/2492.13 (1.13-4.00).02
  HLA-mismatched unrelated24/1014.25 (2.43-7.44)<.001
 Conditioning regimen
  Bu/Cy/TT/FLU17/3721.00<.001
  Bu/Cy/FLU24/2552.03 (1.09-3.78).03
  Bu/Cy41/2236.78 (3.59-12.81)<.001
  Treosulfan/TT/FLU20/1407.25 (3.41-15.41)<.001
  Bu or melphalan ± TT ± FLU9/571.94 (0.82-4.60).13
 Recipient sex
  Male82/6591.00
  Female29/3880.59 (0.38-0.91).02